Evidence map›Paper›PMID 31376094›Full record

ReviewInflammation2020

Activation of Human Eosinophils with Nanoparticles: a New Area of Research.

Marion Vanharen, Denis Girard

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Marion VanharenLaboratoire de Recherche en Inflammation et Physiologie des Granulocytes, INRS-Centre Armand-Frappier Santé Biotechnologie, Université du Québec, 531 boul. des Prairies, Laval, QC, H7V 1B7, Canada.
Denis GirardLaboratoire de Recherche en Inflammation et Physiologie des Granulocytes, INRS-Centre Armand-Frappier Santé Biotechnologie, Université du Québec, 531 boul. des Prairies, Laval, QC, H7V 1B7, Canada. denis.girard@iaf.inrs.ca.
Institut National de la Recherche Scientifique · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is becoming increasingly clear that nanoparticles (NPs) possess many potential applications in both clinical medicine and research. Potential utilization of NPs in nanomedicine for the treatment of respiratory diseases where eosinophils exert pathogenic roles is gaining increasing attention. Even though several NPs were found to possess pro-inflammatory activities in in vivo models based on an increased number of eosinophils in rodent airways, it is not clear how NPs could directly activate eosinophils themselves and how they can alter their biology. In this review, we discuss the most recent data in this new area of research demonstrating that NPs could now be added as new eosinophils modulators. Indeed, activation of eosinophils with NPs could lead to modulation of spontaneous apoptosis, caspase activation, and cytoskeleton breakdown when apoptosis is induced; cytokine production, de novo protein synthesis, cellular adhesion onto a cell substratum, and cell signalling events such as activation of the phosphoinositide 3-kinase/Akt pathway and actin re-localization are involved in NP-induced adhesion. Therefore, future development of therapeutic strategies with NPs aiming at targeting diseases where eosinophils are involved should now consider the capacity of NPs to modulate human eosinophil biology.

Indexed as

AnimalsApoptosisCell AdhesionCytokinesCytoskeletonEosinophilsHumansMetal NanoparticlesSignal TransductionCytokinesapoptosiscellular adhesioncytokinescytoskeletoneosinophilsinflammationnanoparticles

Identifiers

PMID31376094
OpenAlexW2965319336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.